Whether, since her reply to question 194 on 25 April 2012, she has taken any steps to compel (a) departments and (b) entities who report to them to (i) attend meetings and (ii) submit their (aa) mini drug master plans and (bb) departmental reports; if not, what is the position in this regard; if so, what are the relevant details, in each case?